Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

“…3,6 Remarkably, a recent study by the HOVON/SAKK group demonstrated that RIC/nonmyeloablative allo-HCT improved overall survival (OS) in older (60 years of age or older) patients with intermediate or high-risk AML in comparison with those not transplanted. 7 Nevertheless, disease relapse remained the first cause of death even in RIC/nonmyeloablative allo-HCT recipients. 7 The outcome of AML patients who relapse after allo-HCT remains poor.…”

“…7 Nevertheless, disease relapse remained the first cause of death even in RIC/nonmyeloablative allo-HCT recipients. 7 The outcome of AML patients who relapse after allo-HCT remains poor. 8 Donor lymphocyte infusion (DLI) can result in prolonged CR but only in a minority of patients with low-disease burden.…”

Reprint of: Aging: Treating the Older Patient

“…However, limiting the comparison to HLA matched grafts after reducedintensity conditioning showed no major influence of age alone [64,65]. A report by Versluis et al [66] derived from prospective AML studies of patients 60 years and older revealed reduced-intensity transplant from matched related or unrelated donors improved 5-year overall survival rates at 35% versus 26% for other forms of consolidation therapy (hazard ratio [HR] = .71, P = .017).…”

Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin

“…In investigating the association between various events occurring in a trial and OS, the standard approach adopted in many studies has been to employ a Cox regression model using time-dependent covariates [4][5][6][7][8][9]. However, the association between progression type and survival remains to be investigated by this method in gastric cancer.…”